Asia Pacific Biosimilars Market

The Asia Pacific biosimilars market is expected to grow from US$ 3,141.28 million in 2022 to US$ 22,533.11 million by 2028. It is estimated to grow at a CAGR of 38.9% from 2022 to 2028.

Patent Expiry of Blockbuster Biologics is Driving Asia Pacific Biosimilars Market

Biologicals represent promising new therapies for previously incurable diseases and are becoming highly important in the pharmaceuticals market. Patents on originator biologicals are expected to expire in the coming years. The patent expiration and other intellectual property rights for originator biologicals will create a need to introduce new biosimilars in the future. As a result, competition among market players will surge in the industry in the coming years. Thus, the patent expiry of blockbuster biologics is expected to create lucrative opportunities for the biosimilar market during the forecast period.

Asia Pacific Biosimilars Market Overview  

According to Generics and Biosimilars Initiative (GaBI), in 2021, the National Medical Products Administration (NMPA) has approved 13 copy biologicals, within the product classes of monoclonal antibody and tumour necrosis factor (TNF)-inhibitor, for use in China.

In February 2019, China’s first official biosimilar was approved. The rituximab biosimilar HLX01 was developed by Shanghai Henlius Biopharmaceutical for the treatment of Non-Hodgkin’s Lymphoma (NHL). Three more biosimilars were approved in China in 2019, and seven biosimilars were approved in 2020, at an increase of 75% between 2019 and 2020. A bevacizumab biosimilar by Luye Pharma Group Ltd was approved in May 2021 for non-small cell lung cancer, and an infliximab biosimilar by Mabpharm Ltd was approved in July 2021 for ankylosing spondylitis.

Thus, the Chinese biosimilars will continue to surge in the future, with 11 biosimilars in pre-registration awaiting NMPA approval and approximately 100 biosimilars in development. Therefore, China's strong biosimilar pipeline and the NMPA's latest regulation changes will foster growth in China's biosimilar market.

Asia Pacific Biosimilars Market Revenue and Forecast to 2028 (US$ Million)

Asia Pacific Biosimilars Strategic Insights

Strategic insights for the Asia Pacific Biosimilars provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Asia Pacific Biosimilars Report Scope

Asia Pacific Biosimilars Regional Insights

The geographic scope of the Asia Pacific Biosimilars refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

Asia Pacific Biosimilars Market Segmentation

The Asia Pacific biosimilars market is segmented into disease indication, drug class, route of administration, end user, and country.

Based on disease indication, the biosimilars market is segmented into cancer, diabetes, autoimmune diseases, and other disease indications. The cancer segment held the largest market share in 2022.  

The biosimilars market, based on drug class, is segmented into granulocyte colony-stimulating stimulating factors, human growth hormone, insulin, TNF blockers & monoclonal antibodies, erythropoietin-stimulating stimulating agents, and others. The granulocyte colony-stimulating factors segment accounted for the largest share of the market in 2022.

Based on route of administration, the biosimilar market is segmented into intravenous, subcutaneous, and others. The intravenous segment accounted for the largest share of the market in 2022. 

The biosimilars market, based on end user, is segmented into hospitals, specialty clinics, homecare, and others. The hospitals segment accounted for the largest share of the market in 2022.

Based on country, the Asia Pacific biosimilars market is segmented into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. China dominated the market in 2022.

Amgen Inc; Sanofi SA; Biocon Ltd; Eli Lilly and Co; Sandoz AG; Teva Pharmaceutical Industries Ltd; Pfizer Inc; and Dr. Reddy's Laboratories Ltd; Celltrion Inc; Samsung Bioepis Co Ltd are the leading companies operating in the Asia Pacific biosimilars market.